Molecular structure of Oxcarbazepine, CAS Number: 28721-07-5
Oxcarbazepine (CAS 28721-07-5)
Application:
Oxcarbazepine is a sodium channel protein inhibitor
CAS Number:
28721-07-5
Purity:
≥98%
Molecular Weight:
252.27
Molecular Formula:
C15H12N2O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Oxcarbazepine manifests its anticonvulsant properties through distinct mechanisms that contribute to its efficacy. By binding to voltage-gated sodium channels, Oxcarbazepine effectively curtails their activity, leading to a reduction in their function. Furthermore, Oxcarbazepine exerts its influence by binding to and inhibiting the activity of glutamate receptors.
Oxcarbazepine (CAS 28721-07-5) References
- Oxcarbazepine in affective and schizoaffective disorders. | Dietrich, DE., et al. 2001. Pharmacopsychiatry. 34: 242-50. PMID: 11778145
- Oxcarbazepine in the treatment of bipolar disorder: a review. | Pratoomsri, W., et al. 2006. Can J Psychiatry. 51: 540-5. PMID: 16933591
- Oxcarbazepine in the maintenance treatment of bipolar disorder. | Vasudev, A., et al. 2008. Cochrane Database Syst Rev. 2008: CD005171. PMID: 18254071
- Oxcarbazepine for refractory epilepsy: systematic review of the literature. | Saconato, H., et al. 2009. Sao Paulo Med J. 127: 150-9. PMID: 19820875
- Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. | Koch, MW. and Polman, SK. 2009. Cochrane Database Syst Rev. CD006453. PMID: 19821367
- Oxcarbazepine-induced myoclonic status epilepticus in juvenile myoclonic epilepsy. | Fanella, M., et al. 2013. Epileptic Disord. 15: 181-7. PMID: 23774821
- Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. | Tomson, T., et al. 2018. Lancet Neurol. 17: 530-538. PMID: 29680205
- Carbamazepine-, Oxcarbazepine-, Eslicarbazepine-Associated Movement Disorder: A Literature Review. | Rissardo, JP. and Caprara, ALF. 2020. Clin Neuropharmacol. 43: 66-80. PMID: 32384309
- Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. | Bendtsen, L., et al. 2020. Lancet Neurol. 19: 784-796. PMID: 32822636
- Current role of carbamazepine and oxcarbazepine in the management of epilepsy. | Beydoun, A., et al. 2020. Seizure. 83: 251-263. PMID: 33334546
- Population pharmacokinetics of oxcarbazepine: a systematic review. | Chen, YT., et al. 2021. Expert Rev Clin Pharmacol. 14: 853-864. PMID: 33851561
- Adverse fetal and neonatal outcomes following in-utero exposure to oxcarbazepine: A systematic review and meta-analysis. | Athar, F., et al. 2022. Br J Clin Pharmacol. 88: 3600-3609. PMID: 35591806
- Oxcarbazepine and Hyponatremia. | Čiauškaitė, J., et al. 2022. Medicina (Kaunas). 58: PMID: 35629976
- The longitudinal effect of oxcarbazepine on thyroid function in children and adolescents with epilepsy. | Park, H., et al. 2022. Epilepsia. 63: 3148-3155. PMID: 36073252
Inhibitor of:
Sodium Channel Protein.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Oxcarbazepine, 10 mg | sc-204826 | 10 mg | $158.00 |